ABB Wins Major Order to Transmit Wind Power from North Sea
ABB’s Power Grids business has been awarded a triple digit million-euro order from the Aibel/Keppel FELS consortium, which will design, construct, and build the High Voltage Direct Current (HVDC) transmission system for the offshore wind connection project DolWin5. ABB is the HVDC technology provider. This project will deliver 900 megawatts of zero-carbon electricity – enough to power around 1 million homes - from three wind farms some 100 km off the German coast. It is scheduled for completion in 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190510005113/en/
DolWin2 in North Sea (Photo: Business Wire)
The order includes the converter platform in the North Sea, as well as an onshore converter station located in Emden, in the Lower Saxony region of Germany. TenneT, a leading European electricity transmission system operator, with activities in the Netherlands and in Germany, is responsible for providing power links to the offshore wind farms in this cluster.
ABB’s HVDC solution is used to transport the power generated by offshore wind farms very efficiently by converting the alternate current (AC) to direct current (DC) on the converter platform. That makes it possible to transmit the power through a 130-kilometer-long DC cable system with very low losses to the mainland. In the onshore converter station, the power is converted back to AC and then integrated into the transmission grid. ABB HVDC’s offshore wind connection solutions are compact and modular to specifically address the challenges of the offshore wind industry and support a substantial improvement in LCOE (Levelized Cost Of Electricity), as well as carbon footprint.
With the use of ABB’s voltage source converter technology, commercialized under the name HVDC Light®, it is possible to keep the conversion losses very low. Additionally, the order will also include the ABB Ability™ Modular Advanced Control for HVDC (MACHTM), which is instrumental in controlling the complex connection between wind farms and the on-shore AC grid.
“Our innovative HVDC technology, worldwide expertise, deep understanding of the renewables integration challenges, our partnership approach and close collaboration with TenneT, were key differentiators in winning this project,” said Claudio Facchin, President of ABB’s Power Grids business.
As part of its energy transition (“Energiewende”), Germany’s plans to generate 65 percent of its power from renewable sources by 2030. A rapidly growing proportion of this clean energy is generated in huge offshore wind farms in the North Sea. In just 10 years, Germany’s offshore wind production has grown from zero to 6,382 megawatts, making it the world’s second largest offshore wind producer after the UK.
ABB pioneered HVDC more than 60 years ago and has delivered more than half of the world’s HVDC projects and more than 70 percent of the world’s voltage source converter HVDC projects.
ABB (ABBN: SIX Swiss Ex) is a pioneering technology leader with a comprehensive offering for digital industries. With a history of innovation spanning more than 130 years, ABB is today a leader in digital industries with four customer-focused, globally leading businesses: Electrification, Industrial Automation, Motion, and Robotics & Discrete Automation, supported by its common ABB Ability™ digital platform. ABB’s market leading Power Grids business will be divested to Hitachi in 2020. ABB operates in more than 100 countries with about 147,000 employees. www.abb.com
Phone: +41 43 317 71 11
Phone: +41 43 317 71 11
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SHINE Creates Therapeutics Division, Will Attend 2019 European Association of Nuclear Medicine Conference12.10.2019 04:00:00 CEST | Press release
SHINE Medical Technologies, LLC today announced the creation of a new division of the company — SHINE Therapeutics. The establishment of the division enhances the company’s ability to focus on filling critical future needs in the rapidly growing therapeutic isotope market, while continuing to leverage its radioisotope production expertise. The company’s Therapeutics division will initially focus on the development and commercialization of lutetium‑177, or Lu‑177, a therapeutic isotope that is combined with a disease-specific targeting molecule to treat cancer. Targeting molecules deliver Lu‑177 atoms to cancer sites throughout the body, where they directly irradiate cancer cells. The first Lu‑177-based targeted radiotherapy (for neuroendocrine tumors) reached the market in 2018. Many high-potential targeted molecules for the treatment of a range of other cancers with Lu-177 are currently under investigation. SHINE is also evaluating additional medical isotopes with therapeutic properti
Smart Taxation – A Step Towards a Fair, Efficient and Growth-Friendly European Taxation Approach11.10.2019 22:01:00 CEST | Press release
In a rapidly changing global economy, smart taxation is essential to drive growth and economic prosperity. However, the European Union (EU) continues to fall behind as it persists with a one-size-fits all taxation system. This year’s GLOBSEC Tatra Summit hosts a Focus Group, bringing together international experts, looking to reshape and support a smarter European tax policy. Europe is at a crossroads in adapting its tax policy to the realities of today’s global economy. The EU plays a key role in overseeing national tax rules in some areas - particularly in relation to EU business and consumer policies. The institutional changeover marks a perfect opportunity for the Tatra Summit to place major topics on the radar of decision-makers and offer efficient recommendations. So now is the time to adapt the EU’s taxation model to be fit-for-purpose. With member states around the table, European fiscal authorities should design a model that does not have a disruptive impact on national needs
Clovis Oncology Announces Rubraca®▼ (rucaparib) Now Available for Women with Relapsed Ovarian Cancer in England Through the Cancer Drugs Fund11.10.2019 13:19:00 CEST | Press release
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the National Institute for Health and Care Excellence (NICE) has recommended that women with relapsed ovarian cancer in England have access to rucaparib through the Cancer Drugs Fund (CDF).1 Rucaparib is available for use within the CDF as an option for the maintenance treatment of relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy in adults, based on the conditions outlined in the managed access agreement. "Ovacome welcomes the availability of rucaparib via the CDF as an option for maintenance treatment of platinum-sensitive relapsed high grade serous epithelial ovarian cancer regardless of BRCA status or line of treatment in the relapsed maintenance setting,” said Victoria Clare, CEO of Ovacome, a United Kingdom ovarian cancer charity focused on providing support to anyone affected by ovarian cancer. “It is vital that the exp
Yokogawa Releases Dynamic Real Time Optimizer, a New Solution in the OpreX Asset Operations and Optimization Family11.10.2019 02:00:00 CEST | Press release
Yokogawa Electric Corporation (TOKYO:6841) announces the release of Dynamic Real Time Optimizer, a solution in the OpreXTM Asset Operations and Optimization family. Using a combination of first principles simulation and multivariable predictive control technology, the Dynamic Real Time Optimizer software helps to optimize plant operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191010005009/en/ Operating window of Dynamic Real Time Optimizer (Graphic: Yokogawa Electric Corporation) This integrated solution is based on Yokogawa’s advanced process control technologies and industry knowledge and simulation technologies developed by KBC Advanced Technologies Limited (KBC, CEO: Andrew Howell), a UK-based Yokogawa subsidiary. This solution enables plants to quickly respond to dynamically changing oil market and product market conditions and improve both productivity and profitability. Development Background Advanced proces
Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis10.10.2019 22:00:00 CEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of moderately-to-severely active rheumatoid arthritis (RA) are consistent with and support the efficacy, safety and tolerability profiles demonstrated in the Week 12 and 24 analyses presented earlier this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191010005875/en/ “We are encouraged by the durability of both the efficacy and safety profiles of filgotinib seen in these studies,” said John Sundy, MD, PhD, Senior Vice President, Inflammation and Respiratory Diseases, Gilead Sciences. “These data suggest that filgotinib if approved, may play an important role in helping people living with rheumatoid arthritis achieve sustained, clinically meaningful responses.” “The
Gilead Sciences to Release Third Quarter 2019 Financial Results on Thursday, October 24, 201910.10.2019 20:05:00 CEST | Press release
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2019 financial results will be released on Thursday, October 24, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the third quarter 2019 and provide a business update. The live webcast of the call can be accessed at the company’s Investors page at http://investors.gilead.com/. Please connect to the company’s website at least 15 minutes prior to the start of the call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 877-359-9508 (U.S.) or 224-357-2393 (international) and dial the conference ID 6094972 to access the call. Telephone replay will be available approximately two hours after the call through 8:00 p.m. Eastern Time, October 26, 2019. To access the replay, please call 855-859-2056 (U.S.) or 404-537-3406 (international) and dial the con